327 related articles for article (PubMed ID: 22450392)
1. Innovative antifibrotic therapies in systemic sclerosis.
Beyer C; Distler O; Distler JH
Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis.
Jordan S; Chung J; Distler O
Curr Opin Rheumatol; 2013 Nov; 25(6):679-85. PubMed ID: 24047603
[TBL] [Abstract][Full Text] [Related]
3. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast abnormalities in the pathogenesis of systemic sclerosis.
Usategui A; del Rey MJ; Pablos JL
Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292
[TBL] [Abstract][Full Text] [Related]
5. Animal models of scleroderma: lessons from transgenic and knockout mice.
Derrett-Smith EC; Denton CP; Sonnylal S
Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
7. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
[TBL] [Abstract][Full Text] [Related]
8. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
Hasegawa M; Takehara K
Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
[TBL] [Abstract][Full Text] [Related]
9. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
[TBL] [Abstract][Full Text] [Related]
11. Criteria to select molecular targets for anti-fibrotic therapy.
Distler JH; Distler O
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v12-3. PubMed ID: 18784127
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M; Varga J
Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
14. Novel treatment approaches to fibrosis in scleroderma.
Distler J; Distler O
Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis: from pathogenesis to targeted therapy.
Denton CP
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
[TBL] [Abstract][Full Text] [Related]
18. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
[TBL] [Abstract][Full Text] [Related]
19. New pathogenic and therapeutic concepts in systemic sclerosis.
Hügle T; Huigens CA; van Laar JM
Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
